WO2022177078A1 - Antibacterial agent comprising trifluoromethylated hydroquinone - Google Patents

Antibacterial agent comprising trifluoromethylated hydroquinone Download PDF

Info

Publication number
WO2022177078A1
WO2022177078A1 PCT/KR2021/010236 KR2021010236W WO2022177078A1 WO 2022177078 A1 WO2022177078 A1 WO 2022177078A1 KR 2021010236 W KR2021010236 W KR 2021010236W WO 2022177078 A1 WO2022177078 A1 WO 2022177078A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
trifluoromethylated
hydroquinone
present
carbon atoms
Prior art date
Application number
PCT/KR2021/010236
Other languages
French (fr)
Korean (ko)
Inventor
조은진
박태정
이다슬
소니 비닛쿠마르
Original Assignee
중앙대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 중앙대학교 산학협력단 filed Critical 중앙대학교 산학협력단
Publication of WO2022177078A1 publication Critical patent/WO2022177078A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A01N35/06Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing keto or thioketo groups as part of a ring, e.g. cyclohexanone, quinone; Derivatives thereof, e.g. ketals

Definitions

  • the present invention relates to an antimicrobial agent comprising a trifluoromethylated hydroquinone derivative.
  • 1,2-hexanediol is a liquid compound having a boiling point of 220 to 230°C and is harmless to the human body, but has a problem in that a large amount is required to function as a preservative due to its low antibacterial activity.
  • hydroquinone is a phenol-based aromatic organic compound, which is well soluble in water and has strong reducing power, so it has been used as an antioxidant or polymerization inhibitor in food, rubber, etc.
  • 1,2-hexanediol similarly to 1,2-hexanediol, a large amount is required, so there is a problem in that the application of the technology is limited.
  • One object of the present invention is to provide an antibacterial agent comprising a trifluoromethylated hydroquinone derivative having excellent antibacterial effect even in a small amount.
  • the antimicrobial agent according to an embodiment of the present invention includes a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 1:
  • R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, alkyl having 1 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, halogen, and —CF 3 , with the proviso that R 1 , R 2 any one of , R 3 , and R 4 is —CF 3 .
  • any one of R 1 , R 2 , R 3 , and R 4 may be —CF 3 , and the rest may be hydrogen or straight or branched chain alkoxy having 1 to 10 carbon atoms.
  • any one of R 1 , R 2 , R 3 , and R 4 may be —CF 3 , and the remainder may be hydrogen or halogen.
  • any one of R 1 , R 2 , R 3 , and R 4 may be —CF 3 , and the remainder may be hydrogen or a linear or branched alkyl having 1 to 10 carbon atoms.
  • the antimicrobial agent may include a trifluoromethylated hydroquinone derivative represented by any one of the following Chemical Formulas 1-1 to 1-14.
  • the antimicrobial agent according to another embodiment of the present invention includes a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 2:
  • R 11 , R 12 , R 13 , and R 14 are each independently selected from hydrogen or halogen, provided that at least one or more of R 11 , R 12 , R 13 , and R 14 is halogen.
  • the antimicrobial agent may include a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 2-1 or 2-2.
  • the trifluoromethylated hydroquinone derivative of the present invention has an effect of remarkably enhancing the antibacterial effect of hydroquinone by introducing a trifluoro group (-CF 3 ) to hydroquinone.
  • the antibacterial agent of the present invention containing the trifluoromethylated hydroquinone derivative has excellent antibacterial effect even in a small amount, and thus, when applied to industrial preservatives and coatings, it can exhibit a high antibacterial effect even in a small amount, which is an economical advantage There is this.
  • Figure 2 is the result of observing the bactericidal effect of each concentration of the compounds added to the culture medium of the fungus Cryptococcus neoformans .
  • Figure 4 is the result of observing the sterilization effect of each concentration of the compounds added to the culture medium of the fungus Aspergillus niger .
  • substitution in the expression “substituted or unsubstituted” means that a hydrogen atom in one functional group is replaced by another atom or another functional group (ie, a substituent).
  • alkyl may be straight-chain or branched, and may be substituted or unsubstituted.
  • the number of carbon atoms of the alkyl is not particularly limited, but specifically, it may be a straight-chain or branched alkyl having 1 to 10 carbon atoms, more specifically, a straight-chain or branched alkyl having 1 to 4 carbon atoms.
  • Specific examples of the alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl.
  • the "alkoxy” may be a straight chain, branched chain, or cyclic chain, and may be substituted or unsubstituted.
  • the number of carbon atoms of the alkoxy is not particularly limited, and specifically, it may be a straight-chain or branched-chain alkoxy having 1 to 10 carbon atoms, more specifically, a straight-chain or branched-chain alkoxy having 1 to 4 carbon atoms.
  • Specific examples of the alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, and the like.
  • halogen includes F, Cl, Br, and I atoms, and specifically may be F, Cl, or Br atoms.
  • the antimicrobial agent according to an embodiment of the present invention may include a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 1:
  • R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, alkyl having 1 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, halogen, and —CF 3 , any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 .
  • any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 , and the remainder is hydrogen or a linear or branched chain alkyl having 1 to 10 carbon atoms, or hydrogen or a straight chain having 1 to 10 carbon atoms. or branched chain alkoxy, or hydrogen or halogen.
  • antimicrobial agent containing the trifluoromethylated hydroquinone derivative represented by Formula 1 may include the following Formulas 1-1 to 1-14:
  • the antibacterial agent according to another embodiment of the present invention may include a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 2:
  • R 11 , R 12 , R 13 , and R 14 are each independently selected from hydrogen or halogen, provided that at least one of R 11 , R 12 , R 13 , and R 14 is halogen. .
  • antimicrobial agent containing the trifluoromethylated hydroquinone derivative represented by Formula 2 may include Formula 2-1 or Formula 2-2 below:
  • the trifluoromethylated hydroquinone derivative represented by Formula 1 or 2 has an effect of remarkably enhancing the antibacterial effect of hydroquinone by introducing a trifluoro group (-CF 3 ) to the hydroquinone.
  • the antibacterial agent of the present invention containing the trifluoromethylated hydroquinone derivative has excellent antibacterial effect even in a small amount, and thus, when applied to industrial preservatives and coatings, it can exhibit a high antibacterial effect even in a small amount, which is an economical advantage There is this.
  • the trifluoromethylated hydroquinone derivative represented by Formula 1 or Formula 2 is irradiated with light having a wavelength of 380 nm to 500 nm to the benzoquinone derivative in the presence of a trifluoromethylation reagent in a solvent. It can be prepared by reaction.
  • the benzoquinone derivative may be a 1,4-benzoquinone derivative.
  • the benzoquinone derivative may be 1,4-benzoquinone unsubstituted or substituted by one or more substituents selected from alkyl, alkoxy, and halogen, and more specifically, unsubstituted 1,4-benzoquinone. It may be quinone, or 1,4-benzoquinone substituted by one or two substituents selected from linear or branched alkyl having 1 to 10 carbon atoms, straight or branched chain alkoxy having 1 to 10 carbon atoms, and halogen. .
  • the trifluoromethylation reagent is not particularly limited as long as it is commonly used in organic synthesis as a source of trifluoromethyl groups.
  • Commonly used trifluoromethylation reagents include Togni's reagent, Umemoto's reagent, and Langlois' reagent.
  • Togni's reagent and Umemoto's reagent have the advantage of being stable and easy to handle even at room temperature for a long time, but they have the disadvantage of being expensive.
  • Langlois reagent (CF 3 SO 2 Na) is inexpensive, and when used in the preparation of the compound of the present invention, the reaction can proceed smoothly in connection with the starting material, so the use of Langlois reagent as a trifluoromethylation reagent it is preferable
  • the solvent may be water, an organic solvent, or a mixed solvent in which water and an organic solvent are mixed.
  • the organic solvent is not particularly limited as long as it does not react with the reactants, and examples thereof include methanol, ethanol, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile (MeCN), 2,2,2 -trifluoroethanol (TFE), etc. are mentioned, and these may be used individually or in mixture of two or more.
  • the solvent one selected from water, methanol, ethanol, dimethyl sulfoxide, acetonitrile, and 2,2,2-trifluoroethanol more can be used.
  • a mixed solvent in which water and an organic solvent are mixed as the solvent specifically, a mixed solvent in which water and acetonitrile or 2,2,2-trifluoroethanol are mixed is preferable.
  • their mixing ratio is 1:2 to 2:1 (by volume), specifically 1:1.5 to 1.5:1 (by volume), more specifically 1 It may be a ratio of :1 (by volume).
  • Example 4 The reaction was carried out in the same manner as in Example 1, except that 2-chlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. Thus, a compound represented by the following Chemical Formula 1-3 was synthesized. (Existing as a mixture with Example 4)
  • Example 3 The reaction was carried out in the same manner as in Example 1, except that 2-chlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. Thus, a compound represented by the following Chemical Formula 1-4 was synthesized. (Existing as a mixture with Example 3)
  • Saccharomyces cerevisiae B4742, Cryptococcus neoformans H99 (ATCC 208821), Candida albicans (Korea Center for Microorganisms, KCTC 7729), Aspergillus niger (Korea Microorganism Conservation Center) , KCCM 11239) was used as a test cell.
  • albicans strains were cultured in Yeast extract-Peptone-Dextrose (YPD) solid medium (yeast extract 1%, bacto-peptone 2%, glucose 2% and agar 2%) for 48 hours.
  • YPD Yeast extract-Peptone-Dextrose
  • Examples 1 to 6 antibacterial substances synthesized in the present invention, and the standard solutions of Comparative Examples 1 to 2 were prepared by mixing in the culture solution, and then serially diluted in the culture solution to adjust the final concentration range to 4 - 0.0625 mg/mL did.
  • the culture medium used was YPD broth (1% yeast extract, 2% bacto-peptone, 2% glucose) for yeast species, and Potato Dextrose Broth (PDB) for A. niger .
  • the compound of the present invention was cultured using a sterilized test tube so as to overlap three times for each sample.
  • the mixed solution was incubated at 30 °C for 24-48 hours after inoculating the desired number of bacteria per each test tube.
  • the yeast cells of 1.0 ⁇ 10 5 cells per ml were serially diluted and inoculated at 0.1 mL each.
  • the compounds according to the embodiment of the present invention were serially diluted with 1.0 ⁇ 10 4 pieces/ml mold spores and inoculated by 0.1 mL each. Then, the cell concentration was observed at OD 600 in order to evaluate the minimum inhibitory concentration by the compound of the present invention.
  • Example 1 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 and 2 in various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 mg/mL) in a culture medium of yeast S. cerevisiae In addition, it shows the result of observing the absorbance at 600 nm to observe the bactericidal effect while culturing for 48 hours.
  • Figure 2 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 and 2 at various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL in the culture medium of the fungus C. neoformans ) ), and shows the result of observing the absorbance at 600 nm to observe the sterilization effect while culturing for 48 hours.
  • Examples 1 to 6 and Comparative Examples 1 to 2 show the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 to 2 in various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL in a culture medium of yeast C. albicans ) ), and the absorbance was observed at 600 nm to observe the sterilization effect while culturing for 48 hours.
  • Figure 4 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 to 2 in various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL in the culture medium of the fungus A. niger ) ) was added and the absorbance was observed at 600 nm to observe the sterilization effect while culturing for 48 hours.
  • 5 is a graph comparing the sterilization effect by concentration of each compound for four types of cells.
  • Example 5 DS5105) and Example 6 (DS5148) exhibited superior sterilization power compared to Comparative Examples 1 and 2 even at low concentrations, from which a trifluoro group (-CF 3 ) is introduced into hydroquinone. It was confirmed that there was an effect of remarkably enhancing the antibacterial effect of quinone.

Abstract

The present invention relates to an antibacterial agent comprising a trifluoromethylated hydroquinone derivative having an excellent antibacterial effect even in a small amount. The antibacterial agent of the present invention has an excellent antibacterial effect even in a small amount, and for this reason, the present invention can exhibit a high antibacterial effect even in a small amount when applied to industrial preservatives and coatings.

Description

트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 항균제Antimicrobials comprising trifluoromethylated hydroquinone derivatives
본 발명은 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 항균제에 관한 것이다.The present invention relates to an antimicrobial agent comprising a trifluoromethylated hydroquinone derivative.
공업용 방부제 및 코팅제는 종이, 도료, 벽지, 페인트 등에 도포되어 곰팡이의 생성을 막는 역할을 하며, 이러한 공업용 방부제로는 일반적으로, 1,2-헥산디올 2% 용액이 사용되어 왔다.Industrial preservatives and coatings are applied to paper, paints, wallpaper, paints, etc. to prevent the formation of mold, and as these industrial preservatives, a 2% solution of 1,2-hexanediol has been generally used.
1,2-헥산디올은 비점 220 내지 230℃인 액상 화합물로 인체에 무해하나, 항균력이 낮아 방부제의 기능을 하려면 많은 양이 요구되는 문제점이 있다.1,2-hexanediol is a liquid compound having a boiling point of 220 to 230°C and is harmless to the human body, but has a problem in that a large amount is required to function as a preservative due to its low antibacterial activity.
한편, 하이드로퀴논(hydroquinone)은 페놀 계열의 방향족 유기 화합물로서, 물에 잘 용해되고 환원력이 강하기 때문에 이러한 성질을 이용하여 식품, 고무 등에 산화방지제로서 사용되거나 중합 억제제로 사용되어 왔으나, 공업용 방부제 및 코팅제에 적용하는 경우 1,2-헥산디올과 유사하게 많은 양이 필요하기 때문에 기술의 적용이 제한적인 문제점이 존재한다.On the other hand, hydroquinone (hydroquinone) is a phenol-based aromatic organic compound, which is well soluble in water and has strong reducing power, so it has been used as an antioxidant or polymerization inhibitor in food, rubber, etc. When applied to 1,2-hexanediol, similarly to 1,2-hexanediol, a large amount is required, so there is a problem in that the application of the technology is limited.
본 발명의 일 목적은 소량으로도 항균 효과가 뛰어난 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 항균제를 제공하는 것이다.One object of the present invention is to provide an antibacterial agent comprising a trifluoromethylated hydroquinone derivative having excellent antibacterial effect even in a small amount.
본 발명의 일 실시예에 따른 항균제는 하기 화학식 1로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함한다:The antimicrobial agent according to an embodiment of the present invention includes a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 1:
[화학식 1][Formula 1]
Figure PCTKR2021010236-appb-img-000001
Figure PCTKR2021010236-appb-img-000001
상기 화학식 1에서,In Formula 1,
R1, R2, R3, 및 R4 는 각각 독립적으로, 수소, 탄소수 1 내지 10의 알킬, 탄소수 1 내지 10의 알콕시, 할로겐, 및 -CF3 에서 선택되고, 단, R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이다.R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, alkyl having 1 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, halogen, and —CF 3 , with the proviso that R 1 , R 2 any one of , R 3 , and R 4 is —CF 3 .
일 실시예에서, 상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알콕시일 수 있다.In one embodiment, any one of R 1 , R 2 , R 3 , and R 4 may be —CF 3 , and the rest may be hydrogen or straight or branched chain alkoxy having 1 to 10 carbon atoms.
일 실시예에서, 상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 할로겐일 수 있다.In an embodiment, any one of R 1 , R 2 , R 3 , and R 4 may be —CF 3 , and the remainder may be hydrogen or halogen.
일 실시예에서, 상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알킬일 수 있다.In one embodiment, any one of R 1 , R 2 , R 3 , and R 4 may be —CF 3 , and the remainder may be hydrogen or a linear or branched alkyl having 1 to 10 carbon atoms.
일 실시예에서, 상기 항균제는 하기 화학식 1-1 내지 1-14 중 어느 하나에 의해 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함할 수 있다.In one embodiment, the antimicrobial agent may include a trifluoromethylated hydroquinone derivative represented by any one of the following Chemical Formulas 1-1 to 1-14.
[화학식 1-1][Formula 1-1]
Figure PCTKR2021010236-appb-img-000002
Figure PCTKR2021010236-appb-img-000002
[화학식 1-2][Formula 1-2]
Figure PCTKR2021010236-appb-img-000003
Figure PCTKR2021010236-appb-img-000003
[화학식 1-3][Formula 1-3]
Figure PCTKR2021010236-appb-img-000004
Figure PCTKR2021010236-appb-img-000004
[화학식 1-4][Formula 1-4]
Figure PCTKR2021010236-appb-img-000005
Figure PCTKR2021010236-appb-img-000005
[화학식 1-5][Formula 1-5]
Figure PCTKR2021010236-appb-img-000006
Figure PCTKR2021010236-appb-img-000006
[화학식 1-6][Formula 1-6]
Figure PCTKR2021010236-appb-img-000007
Figure PCTKR2021010236-appb-img-000007
[화학식 1-7][Formula 1-7]
Figure PCTKR2021010236-appb-img-000008
Figure PCTKR2021010236-appb-img-000008
[화학식 1-8][Formula 1-8]
Figure PCTKR2021010236-appb-img-000009
Figure PCTKR2021010236-appb-img-000009
[화학식 1-9][Formula 1-9]
Figure PCTKR2021010236-appb-img-000010
Figure PCTKR2021010236-appb-img-000010
[화학식 1-10][Formula 1-10]
Figure PCTKR2021010236-appb-img-000011
Figure PCTKR2021010236-appb-img-000011
[화학식 1-11][Formula 1-11]
Figure PCTKR2021010236-appb-img-000012
Figure PCTKR2021010236-appb-img-000012
[화학식 1-12][Formula 1-12]
Figure PCTKR2021010236-appb-img-000013
Figure PCTKR2021010236-appb-img-000013
[화학식 1-13][Formula 1-13]
Figure PCTKR2021010236-appb-img-000014
Figure PCTKR2021010236-appb-img-000014
[화학식 1-14][Formula 1-14]
Figure PCTKR2021010236-appb-img-000015
Figure PCTKR2021010236-appb-img-000015
본 발명의 다른 실시예에 따른 항균제는 하기 화학식 2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함한다:The antimicrobial agent according to another embodiment of the present invention includes a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 2:
[화학식 2][Formula 2]
Figure PCTKR2021010236-appb-img-000016
Figure PCTKR2021010236-appb-img-000016
상기 화학식 2에서,In Formula 2,
R11, R12, R13, 및 R14 는 각각 독립적으로, 수소 또는 할로겐에서 선택되고, 단, R11, R12, R13, 및 R14 중 적어도 하나 이상은 할로겐이다.R 11 , R 12 , R 13 , and R 14 are each independently selected from hydrogen or halogen, provided that at least one or more of R 11 , R 12 , R 13 , and R 14 is halogen.
일 실시예에서, 상기 항균제는 하기 화학식 2-1 또는 2-2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함할 수 있다.In one embodiment, the antimicrobial agent may include a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 2-1 or 2-2.
[화학식 2-1][Formula 2-1]
Figure PCTKR2021010236-appb-img-000017
Figure PCTKR2021010236-appb-img-000017
[화학식 2-2][Formula 2-2]
Figure PCTKR2021010236-appb-img-000018
Figure PCTKR2021010236-appb-img-000018
본 발명의 트리플루오로메틸화 하이드로퀴논 유도체는 하이드로퀴논에 트라이플루오로기(-CF3)가 도입되어 하이드로퀴논의 항균 효과를 현저히 증진시키는 효과가 있다.The trifluoromethylated hydroquinone derivative of the present invention has an effect of remarkably enhancing the antibacterial effect of hydroquinone by introducing a trifluoro group (-CF 3 ) to hydroquinone.
따라서, 상기 트리플루오로메틸화 하이드로퀴논 유도체를 포함하는 본 발명의 항균제는 소량으로도 항균 효과가 뛰어나며, 이로 인해 공업용 방부제 및 코팅제에 적용하는 경우 적은 양으로도 높은 항균 효과를 나타낼 수 있어 경제적인 이점이 있다.Therefore, the antibacterial agent of the present invention containing the trifluoromethylated hydroquinone derivative has excellent antibacterial effect even in a small amount, and thus, when applied to industrial preservatives and coatings, it can exhibit a high antibacterial effect even in a small amount, which is an economical advantage There is this.
도 1은 효모 Saccharomyces cerevisiae의 배양액에 추가된 화합물들의 농도별 살균효과를 관찰한 결과이다.1 is a result of observing the sterilization effect of each concentration of the compounds added to the culture medium of the yeast Saccharomyces cerevisiae .
도 2는 곰팡이 Cryptococcus neoformans의 배양액에 추가된 화합물들의 농도별 살균효과를 관찰한 결과이다.Figure 2 is the result of observing the bactericidal effect of each concentration of the compounds added to the culture medium of the fungus Cryptococcus neoformans .
도 3은 효모 Candida albicans의 배양액에 추가된 화합물들의 농도별 살균효과를 관찰한 결과이다.3 is a result of observing the sterilization effect of each concentration of the compounds added to the culture medium of the yeast Candida albicans .
도 4는 곰팡이 Aspergillus niger의 배양액에 추가된 화합물들의 농도별 살균효과를 관찰한 결과이다.Figure 4 is the result of observing the sterilization effect of each concentration of the compounds added to the culture medium of the fungus Aspergillus niger .
도 5는 4종의 균체에 대해 각 화합물의 농도별 살균효과를 비교한 결과이다.5 is a result of comparing the sterilization effect of each compound concentration for 4 types of cells.
이하, 본 발명에 대해 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 출원에서 사용한 용어는 단지 특정한 구현예를 설명하기 위해 사용된 것으로서 본 발명을 한정하려는 의도가 아니다. 다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. The terminology used in this application is only used to describe specific embodiments and is not intended to limit the present invention. Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
본 명세서에서, 어떤 부분이 어떤 구성요소를 "포함"한다, "함유"한다, "가지다" 라고 할 때, 이는 특별히 달리 정의되지 않는 한, 다른 구성 요소를 더 포함할 수 있다는 것을 의미한다.In this specification, when a part "includes", "contains", or "has" a certain component, it means that other components may be further included unless otherwise defined.
본 명세서에서, "치환 또는 비치환"이란 표현에서 "치환"은 어떤 작용기에서 수소 원자가 다른 원자 또는 다른 작용기 (즉, 치환체)로 대체되는 것을 뜻한다.As used herein, "substitution" in the expression "substituted or unsubstituted" means that a hydrogen atom in one functional group is replaced by another atom or another functional group (ie, a substituent).
본 명세서에서, "알킬"은 직쇄 또는 분지쇄일 수 있으며, 치환 또는 비치환된 것일 수 있다. 상기 알킬의 탄소수는 특별히 한정되지 않으나, 구체적으로는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알킬, 더 구체적으로는 탄소수 1 내지 4의 직쇄 또는 분지쇄 알킬일 수 있다. 상기 알킬의 구체적 예로는 메틸, 에틸, n-프로필, 이소프로필, n-부틸, 이소부틸 및 tert-부틸 등을 들 수 있다. As used herein, "alkyl" may be straight-chain or branched, and may be substituted or unsubstituted. The number of carbon atoms of the alkyl is not particularly limited, but specifically, it may be a straight-chain or branched alkyl having 1 to 10 carbon atoms, more specifically, a straight-chain or branched alkyl having 1 to 4 carbon atoms. Specific examples of the alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl.
본 명세서에서, 상기 "알콕시"는 직쇄, 분지쇄, 또는 고리쇄일 수 있으며, 치환 또는 비치환된 것일 수 있다. 상기 알콕시의 탄소수는 특별히 한정되지 않으나, 구체적으로는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알콕시, 더 구체적으로는 탄소수 1 내지 4의 직쇄 또는 분지쇄 알콕시일 수 있다. 상기 알콕시의 구체적 예로는, 메톡시, 에톡시, n-프로폭시, 이소프로폭시, n-부톡시, sec-부톡시, tert-부톡시 등을 들 수 있다.In the present specification, the "alkoxy" may be a straight chain, branched chain, or cyclic chain, and may be substituted or unsubstituted. The number of carbon atoms of the alkoxy is not particularly limited, and specifically, it may be a straight-chain or branched-chain alkoxy having 1 to 10 carbon atoms, more specifically, a straight-chain or branched-chain alkoxy having 1 to 4 carbon atoms. Specific examples of the alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, and the like.
본 명세서에서, "할로겐"은 F, Cl, Br, 및 I 원자를 포함하며, 구체적으로는 F, Cl 또는 Br 원자일 수 있다.As used herein, "halogen" includes F, Cl, Br, and I atoms, and specifically may be F, Cl, or Br atoms.
본 발명의 일 실시예에 따른 항균제는 하기 화학식 1로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함할 수 있다:The antimicrobial agent according to an embodiment of the present invention may include a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 1:
[화학식 1][Formula 1]
Figure PCTKR2021010236-appb-img-000019
Figure PCTKR2021010236-appb-img-000019
상기 화학식 1에서, R1, R2, R3, 및 R4 는 각각 독립적으로, 수소, 탄소수 1 내지 10의 알킬, 탄소수 1 내지 10의 알콕시, 할로겐, 및 -CF3 에서 선택되고, 단, R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이다.In Formula 1, R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, alkyl having 1 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, halogen, and —CF 3 , any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 .
구체적으로는, 상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알킬이거나, 수소 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알콕시이거나, 또는 수소 또는 할로겐일 수 있다.Specifically, any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 , and the remainder is hydrogen or a linear or branched chain alkyl having 1 to 10 carbon atoms, or hydrogen or a straight chain having 1 to 10 carbon atoms. or branched chain alkoxy, or hydrogen or halogen.
상기 화학식 1로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 항균제의 구체적인 예로는 하기 화학식 1-1 내지 1-14를 들 수 있다:Specific examples of the antimicrobial agent containing the trifluoromethylated hydroquinone derivative represented by Formula 1 may include the following Formulas 1-1 to 1-14:
[화학식 1-1][Formula 1-1]
Figure PCTKR2021010236-appb-img-000020
Figure PCTKR2021010236-appb-img-000020
[화학식 1-2][Formula 1-2]
Figure PCTKR2021010236-appb-img-000021
Figure PCTKR2021010236-appb-img-000021
[화학식 1-3][Formula 1-3]
Figure PCTKR2021010236-appb-img-000022
Figure PCTKR2021010236-appb-img-000022
[화학식 1-4][Formula 1-4]
Figure PCTKR2021010236-appb-img-000023
Figure PCTKR2021010236-appb-img-000023
[화학식 1-5][Formula 1-5]
Figure PCTKR2021010236-appb-img-000024
Figure PCTKR2021010236-appb-img-000024
[화학식 1-6][Formula 1-6]
Figure PCTKR2021010236-appb-img-000025
Figure PCTKR2021010236-appb-img-000025
[화학식 1-7][Formula 1-7]
Figure PCTKR2021010236-appb-img-000026
Figure PCTKR2021010236-appb-img-000026
[화학식 1-8][Formula 1-8]
Figure PCTKR2021010236-appb-img-000027
Figure PCTKR2021010236-appb-img-000027
[화학식 1-9][Formula 1-9]
Figure PCTKR2021010236-appb-img-000028
Figure PCTKR2021010236-appb-img-000028
[화학식 1-10][Formula 1-10]
Figure PCTKR2021010236-appb-img-000029
Figure PCTKR2021010236-appb-img-000029
[화학식 1-11][Formula 1-11]
Figure PCTKR2021010236-appb-img-000030
Figure PCTKR2021010236-appb-img-000030
[화학식 1-12][Formula 1-12]
Figure PCTKR2021010236-appb-img-000031
Figure PCTKR2021010236-appb-img-000031
[화학식 1-13][Formula 1-13]
Figure PCTKR2021010236-appb-img-000032
Figure PCTKR2021010236-appb-img-000032
[화학식 1-14][Formula 1-14]
Figure PCTKR2021010236-appb-img-000033
Figure PCTKR2021010236-appb-img-000033
한편, 본 발명의 다른 실시예에 따른 항균제는 하기 화학식 2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함할 수 있다:Meanwhile, the antibacterial agent according to another embodiment of the present invention may include a trifluoromethylated hydroquinone derivative represented by the following Chemical Formula 2:
[화학식 2][Formula 2]
Figure PCTKR2021010236-appb-img-000034
Figure PCTKR2021010236-appb-img-000034
상기 화학식 2에서, R11, R12, R13, 및 R14 는 각각 독립적으로, 수소 또는 할로겐에서 선택되고, 단, R11, R12, R13, 및 R14 중 적어도 하나 이상은 할로겐이다.In Formula 2, R 11 , R 12 , R 13 , and R 14 are each independently selected from hydrogen or halogen, provided that at least one of R 11 , R 12 , R 13 , and R 14 is halogen. .
상기 화학식 2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 항균제의 구체적인 예로는 하기 화학식 2-1 또는 화학식 2-2를 들 수 있다:Specific examples of the antimicrobial agent containing the trifluoromethylated hydroquinone derivative represented by Formula 2 may include Formula 2-1 or Formula 2-2 below:
[화학식 2-1][Formula 2-1]
Figure PCTKR2021010236-appb-img-000035
Figure PCTKR2021010236-appb-img-000035
[화학식 2-2][Formula 2-2]
Figure PCTKR2021010236-appb-img-000036
Figure PCTKR2021010236-appb-img-000036
상기 화학식 1 또는 2로 표시되는 트리플루오로메틸화 하이드로퀴논 유도체는 하이드로퀴논에 트라이플루오로기(-CF3)가 도입되어 하이드로퀴논의 항균 효과를 현저히 증진시키는 효과가 있다.The trifluoromethylated hydroquinone derivative represented by Formula 1 or 2 has an effect of remarkably enhancing the antibacterial effect of hydroquinone by introducing a trifluoro group (-CF 3 ) to the hydroquinone.
따라서, 상기 트리플루오로메틸화 하이드로퀴논 유도체를 포함하는 본 발명의 항균제는 소량으로도 항균 효과가 뛰어나며, 이로 인해 공업용 방부제 및 코팅제에 적용하는 경우 적은 양으로도 높은 항균 효과를 나타낼 수 있어 경제적인 이점이 있다.Therefore, the antibacterial agent of the present invention containing the trifluoromethylated hydroquinone derivative has excellent antibacterial effect even in a small amount, and thus, when applied to industrial preservatives and coatings, it can exhibit a high antibacterial effect even in a small amount, which is an economical advantage There is this.
한편, 일 실시예에서, 상기 화학식 1 또는 화학식 2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체는 용매 중에서 트리플루오로메틸화 시약의 존재 하에 벤조퀴논 유도체에 380 nm 내지 500 nm 파장의 광을 조사하여 반응시켜 제조될 수 있다.Meanwhile, in one embodiment, the trifluoromethylated hydroquinone derivative represented by Formula 1 or Formula 2 is irradiated with light having a wavelength of 380 nm to 500 nm to the benzoquinone derivative in the presence of a trifluoromethylation reagent in a solvent. It can be prepared by reaction.
일 실시예에서, 상기 벤조퀴논 유도체는 1,4-벤조퀴논 유도체일 수 있다. 상기 벤조퀴논 유도체는 구체적으로는 알킬, 알콕시, 및 할로겐에서 선택되는 1종 이상의 치환기에 의해 치환 또는 비치환된 1,4-벤조퀴논일 수 있고, 더 구체적으로는 비치환된 1,4-벤조퀴논, 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알킬, 탄소수 1 내지 10의 직쇄 또는 분지쇄 알콕시, 및 할로겐에서 선택되는 1종 또는 2종의 치환기에 의해 치환된 1,4-벤조퀴논일 수 있다.In one embodiment, the benzoquinone derivative may be a 1,4-benzoquinone derivative. Specifically, the benzoquinone derivative may be 1,4-benzoquinone unsubstituted or substituted by one or more substituents selected from alkyl, alkoxy, and halogen, and more specifically, unsubstituted 1,4-benzoquinone. It may be quinone, or 1,4-benzoquinone substituted by one or two substituents selected from linear or branched alkyl having 1 to 10 carbon atoms, straight or branched chain alkoxy having 1 to 10 carbon atoms, and halogen. .
일 실시예에서, 상기 트리플루오로메틸화 시약은 트리플루오로메틸기의 공급원으로서 유기 합성 반응에서 통상적으로 사용되는 것이라면 특별히 제한되지 않는다. 일반적으로 사용되는 트리플루오로메틸화 시약은 Togni 시약, Umemoto 시약, Langlois 시약 등을 들 수 있다. Togni 시약과 Umemoto 시약은 상온에 오래 두어도 안정하고 다루기 쉽다는 장점이 있으나 값이 비싸다는 단점이 있다. Langlois 시약 (CF3SO2Na)은 값이 저렴하며, 본 발명의 화합물의 제조에 사용하였을 때 출발물질과 연계하여 반응을 원활히 잘 진행시킬 수 있으므로, 트리플루오로메틸화 시약으로서 Langlois 시약을 사용하는 것이 바람직하다.In one embodiment, the trifluoromethylation reagent is not particularly limited as long as it is commonly used in organic synthesis as a source of trifluoromethyl groups. Commonly used trifluoromethylation reagents include Togni's reagent, Umemoto's reagent, and Langlois' reagent. Togni's reagent and Umemoto's reagent have the advantage of being stable and easy to handle even at room temperature for a long time, but they have the disadvantage of being expensive. Langlois reagent (CF 3 SO 2 Na) is inexpensive, and when used in the preparation of the compound of the present invention, the reaction can proceed smoothly in connection with the starting material, so the use of Langlois reagent as a trifluoromethylation reagent it is preferable
일 실시예에서, 상기 용매는 물, 유기 용매 또는 물과 유기용매를 혼합한 혼합 용매일 수 있다. 상기 유기 용매로는 반응 물질들과 반응하지 않는 것이라면 특별히 제한되지 않으며, 이의 예로는 메탄올, 에탄올, 디메틸포름아미드(DMF), 디메틸설폭시드(DMSO), 아세토니트릴(MeCN), 2,2,2-트리플루오로에탄올(TFE) 등을 들 수 있고, 이들을 단독으로 또는 둘 이상 혼합하여 사용하여도 좋다. 반응물의 용해성, 제거의 용해성, 반응 효율, 수율 등을 고려하였을 때, 상기 용매로서 물, 메탄올, 에탄올, 디메틸 설폭시드, 아세토니트릴, 및 2,2,2-트리플루오로에탄올에서 선택되는 1종 이상을 사용할 수 있다. 제조 수율의 측면에서 상기 용매로서 물과 유기 용매를 혼합한 혼합 용매, 구체적으로는 물과, 아세토니트릴 또는 2,2,2-트리플루오로에탄올을 혼합한 혼합 용매가 바람직하다. 물과 유기 용매를 혼합할 경우, 이들의 혼합 비율은 1:2 내지 2:1 (부피 기준)의 비율, 구체적으로는 1:1.5 내지 1.5:1 (부피 기준)의 비율, 더 구체적으로는 1:1 (부피 기준)의 비율일 수 있다.In one embodiment, the solvent may be water, an organic solvent, or a mixed solvent in which water and an organic solvent are mixed. The organic solvent is not particularly limited as long as it does not react with the reactants, and examples thereof include methanol, ethanol, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile (MeCN), 2,2,2 -trifluoroethanol (TFE), etc. are mentioned, and these may be used individually or in mixture of two or more. Considering the solubility of reactants, solubility of removal, reaction efficiency, yield, etc., as the solvent, one selected from water, methanol, ethanol, dimethyl sulfoxide, acetonitrile, and 2,2,2-trifluoroethanol more can be used. In terms of production yield, a mixed solvent in which water and an organic solvent are mixed as the solvent, specifically, a mixed solvent in which water and acetonitrile or 2,2,2-trifluoroethanol are mixed is preferable. When mixing water and an organic solvent, their mixing ratio is 1:2 to 2:1 (by volume), specifically 1:1.5 to 1.5:1 (by volume), more specifically 1 It may be a ratio of :1 (by volume).
이하에서는 실시예에 기초하여 본 발명에 대해 더욱 상세하게 설명한다. 그러나, 본 발명이 이러한 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail based on examples. However, the present invention is not limited to these examples.
1. 실시예1. Examples
[실시예 1] 2-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 1] Preparation of 2-(trifluoromethyl)benzene-1,4-diol
상온에서 아르곤(Ar) 분위기 하에 1 mmol의 Langlois 시약 및 3 mmol의 1,4-벤조퀴논을 TFE/H2O (1/1, 0.2 M)에 용해시키고 청색 LED (18 W)로 광 조사하면서 6 시간 동안 반응시켰다. 이로써 2-(트리플루오로메틸)벤젠-1,4-디올을 백색 고체로서 수득하였다.Dissolving 1 mmol of Langlois reagent and 3 mmol of 1,4-benzoquinone in TFE/H 2 O (1/1, 0.2 M) under an argon (Ar) atmosphere at room temperature and irradiating light with a blue LED (18 W) The reaction was carried out for 6 hours. This gave 2-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000037
Figure PCTKR2021010236-appb-img-000037
[실시예 2] 3,5-디메톡시-2-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 2] Preparation of 3,5-dimethoxy-2-(trifluoromethyl)benzene-1,4-diol
출발물질로서 1,4-벤조퀴논을 대신하여 2,6-디메톡시벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 3,5-디메톡시-2-(트리플루오로메틸)벤젠-1,4-디올을 백색 고체로서 수득하였다.The reaction was carried out in the same manner as in Example 1, except that 2,6-dimethoxybenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 3,5-dimethoxy-2-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000038
Figure PCTKR2021010236-appb-img-000038
[실시예 3] [Example 3]
출발물질로서 1,4-벤조퀴논을 대신하여 2-클로로벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 하기 화학식 1-3으로 표시되는 화합물을 합성하였다. (실시예 4와 혼합물로 존재)The reaction was carried out in the same manner as in Example 1, except that 2-chlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. Thus, a compound represented by the following Chemical Formula 1-3 was synthesized. (Existing as a mixture with Example 4)
[화학식 1-3][Formula 1-3]
Figure PCTKR2021010236-appb-img-000039
Figure PCTKR2021010236-appb-img-000039
[실시예 4][Example 4]
출발물질로서 1,4-벤조퀴논을 대신하여 2-클로로벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 하기 화학식 1-4로 표시되는 화합물을 합성하였다. (실시예 3과 혼합물로 존재)The reaction was carried out in the same manner as in Example 1, except that 2-chlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. Thus, a compound represented by the following Chemical Formula 1-4 was synthesized. (Existing as a mixture with Example 3)
[화학식 1-4][Formula 1-4]
Figure PCTKR2021010236-appb-img-000040
Figure PCTKR2021010236-appb-img-000040
[실시예 5][Example 5]
출발물질로서 1,4-벤조퀴논을 대신하여 2,6-디클로로벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 2,6-디메틸-4-(트리플루오로메틸)벤젠-1,4-디올을 백색 고체로서 수득하였다.The reaction was carried out in the same manner as in Example 1, except that 2,6-dichlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 2,6-dimethyl-4-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000041
Figure PCTKR2021010236-appb-img-000041
[실시예 6] 2-클로로-3-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 6] Preparation of 2-chloro-3-(trifluoromethyl)benzene-1,4-diol
출발물질로서 1,4-벤조퀴논을 대신하여 2-클로로벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 2-클로로-3-(트리플루오로메틸)벤젠-1,4-디올이 백색 고체로서 수득되었다.The reaction was carried out in the same manner as in Example 1, except that 2-chlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 2-chloro-3-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000042
Figure PCTKR2021010236-appb-img-000042
[실시예 7] 3,5-디메틸-2-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 7] Preparation of 3,5-dimethyl-2-(trifluoromethyl)benzene-1,4-diol
출발물질로서 1,4-벤조퀴논을 대신하여 2,6-디메틸벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 3,5-디메틸-2-(트리플루오로메틸)벤젠-1,4-디올을 백색 고체로서 수득하였다.The reaction was carried out in the same manner as in Example 1, except that 2,6-dimethylbenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 3,5-dimethyl-2-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000043
Figure PCTKR2021010236-appb-img-000043
[실시예 8] 2,5-디메틸-2-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 8] Preparation of 2,5-dimethyl-2-(trifluoromethyl)benzene-1,4-diol
출발물질로서 1,4-벤조퀴논을 대신하여 2,5-디메틸벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 2,5-디메틸-2-(트리플루오로메틸)벤젠-1,4-디올을 백색 고체로서 수득하였다.The reaction was carried out in the same manner as in Example 1, except that 2,5-dimethylbenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 2,5-dimethyl-2-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000044
Figure PCTKR2021010236-appb-img-000044
[실시예 9] 2-메틸-3-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 9] Preparation of 2-methyl-3-(trifluoromethyl)benzene-1,4-diol
출발물질로서 1,4-벤조퀴논을 대신하여 2-메틸벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 2-메틸-3-(트리플루오로메틸)벤젠-1,4-디올(2-메틸하이드로퀴논과 혼합된 형태)을 백색 고체로서 수득하였다.The reaction was carried out in the same manner as in Example 1, except that 2-methylbenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 2-methyl-3-(trifluoromethyl)benzene-1,4-diol (in admixture with 2-methylhydroquinone) as a white solid.
Figure PCTKR2021010236-appb-img-000045
Figure PCTKR2021010236-appb-img-000045
[실시예 10] 2-메틸-5-(트리플루오로메틸)벤젠-1,4-디올의 제조[Example 10] Preparation of 2-methyl-5-(trifluoromethyl)benzene-1,4-diol
출발물질로서 1,4-벤조퀴논을 대신하여 2-메틸벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 2-메틸-5-(트리플루오로메틸)벤젠-1,4-디올과 2-메틸-6-(트리플루오로메틸)벤젠-1,4-디올의 혼합물을 백색 고체로서 수득하였다.The reaction was carried out in the same manner as in Example 1, except that 2-methylbenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave a mixture of 2-methyl-5-(trifluoromethyl)benzene-1,4-diol and 2-methyl-6-(trifluoromethyl)benzene-1,4-diol as a white solid.
Figure PCTKR2021010236-appb-img-000046
Figure PCTKR2021010236-appb-img-000046
[실시예 11] 3,5-디클로로-4-(트리플루오로메톡시)페놀의 제조[Example 11] Preparation of 3,5-dichloro-4- (trifluoromethoxy) phenol
출발물질로서 1,4-벤조퀴논을 대신하여 2,5-디클로로벤조퀴논을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켰다. 이로써 3,5-디클로로-4-(트리플루오로메톡시)페놀이 백색 고체로서 수득되었다.The reaction was carried out in the same manner as in Example 1, except that 2,5-dichlorobenzoquinone was used instead of 1,4-benzoquinone as a starting material. This gave 3,5-dichloro-4-(trifluoromethoxy)phenol as a white solid.
Figure PCTKR2021010236-appb-img-000047
Figure PCTKR2021010236-appb-img-000047
[비교예 1][Comparative Example 1]
비교예 1로 하기 화학식 3으로 표시되는 하이드로퀴논 화합물을 준비하였다.As Comparative Example 1, a hydroquinone compound represented by the following Chemical Formula 3 was prepared.
[화학식 3][Formula 3]
Figure PCTKR2021010236-appb-img-000048
Figure PCTKR2021010236-appb-img-000048
[비교예 2][Comparative Example 2]
비교예 2로 하기 화학식 4로 표시되는 1,2-헥산디올을 준비하였다.As Comparative Example 2, 1,2-hexanediol represented by the following Chemical Formula 4 was prepared.
[화학식 4][Formula 4]
Figure PCTKR2021010236-appb-img-000049
Figure PCTKR2021010236-appb-img-000049
실험예 1: 균체 서스펜션 준비Experimental Example 1: Preparation of cell suspension
본 발명의 실시예 1 내지 6, 비교예 1 내지 2 화합물들의 항균 실험에서는 Saccharomyces cerevisiae B4742, Cryptococcus neoformans H99 (ATCC 208821), Candida albicans (한국미생물자원센터, KCTC 7729), Aspergillus niger (한국미생물보존센터, KCCM 11239)를 시험균체로 사용하였다. S. cerevisiae, C. neoformans, C. albicans 균주는 48시간 동안 Yeast extract-Peptone-Dextrose (YPD) 고체배지(효모 추출물 1%, bacto-peptone 2%, 포도당 2% 및 한천 2%)에서 배양하였고, A. niger는 테스트 전 4-5일 동안 Potato Dextrose Agar (PDA, 감자 덱스트로스 한천) 고체배지에서 배양하였다. 효모 세포의 수는 3.0 Х 107 의 세포와 동등한 OD600=1.0 을 고려하여 조정되었다.In the antibacterial experiments of the compounds of Examples 1 to 6 and Comparative Examples 1 and 2 of the present invention, Saccharomyces cerevisiae B4742, Cryptococcus neoformans H99 (ATCC 208821), Candida albicans (Korea Center for Microorganisms, KCTC 7729), Aspergillus niger (Korea Microorganism Conservation Center) , KCCM 11239) was used as a test cell. S. cerevisiae , C. neoformans , C. albicans strains were cultured in Yeast extract-Peptone-Dextrose (YPD) solid medium (yeast extract 1%, bacto-peptone 2%, glucose 2% and agar 2%) for 48 hours. , A. niger were cultured in Potato Dextrose Agar (PDA, potato dextrose agar) solid medium for 4-5 days before testing. The number of yeast cells was adjusted to account for an OD 600 =1.0 equivalent to a cell of 3.0 Х 10 7 .
곰팡이 균체는 0.01%(v/v) Triton X-100을 함유한 멸균 식염수로 부양시키고 멸균된 스프레더를 사용하여 균사체에서 포자를 제거함으로써 A. niger 평판 배양액에서 수확했다. 포자가 있는 용액은 세포 여과기를 통해 여과되어 존재하는 균사체와 분리되었다. 포자 수는 OD530=0.5일 때 4.3 Х 106 포자/mL(Petrikkou E. 등, J. Clin. Microbiol. 2001, 39(4):1345-1347)와 동등한 것으로 간주하여 조정되었다. 이렇게 준비된 균체들은 이후 사용 시까지 4°C로 유지되었다.Fungal cells were harvested from A. niger plate cultures by lifting them with sterile saline containing 0.01% (v/v) Triton X-100 and removing spores from the mycelium using a sterile spreader. The spore-bearing solution was filtered through a cell strainer to separate the mycelium present. The spore count was adjusted to be considered equivalent to 4.3 Х 10 6 spores/mL (Petrikkou E. et al., J. Clin. Microbiol. 2001, 39(4):1345-1347) at OD 530 =0.5. The cells thus prepared were maintained at 4 °C until further use.
실험예 2: 액상 살균 효과 분석Experimental Example 2: Analysis of liquid sterilization effect
Figure PCTKR2021010236-appb-img-000050
Figure PCTKR2021010236-appb-img-000050
육수 미세 희석 방법(broth microdilution method)에 의한 항균 민감성 테스트는 유럽 항균 민감성 테스트 위원회(EUCAST)의 규정에 따라 테스트하기 위해 실험예 1에서 준비한 모든 균종들이 사용되었다.For the antibacterial sensitivity test by the broth microdilution method, all strains prepared in Experimental Example 1 were used to test according to the regulations of the European Antimicrobial Sensitivity Test Committee (EUCAST).
본 발명에서 합성한 실시예 1 내지 6 항균물질과, 비교예 1 내지 2의 표준 용액은 배양액에 혼합하여 조제하였고, 그 후 배양액에 연속적으로 희석하여 최종 농도 범위를 4 - 0.0625 mg/mL로 조정하였다. 사용된 배양 배지는 효모 종에 대한 YPD 액상배지(1% 효모 추출물, 2% bacto-peptone, 2% 포도당)였고, A. niger의 경우 감자 덱스트로스 액상배지(Potato Dextrose Broth; PDB)였다.Examples 1 to 6 antibacterial substances synthesized in the present invention, and the standard solutions of Comparative Examples 1 to 2 were prepared by mixing in the culture solution, and then serially diluted in the culture solution to adjust the final concentration range to 4 - 0.0625 mg/mL did. The culture medium used was YPD broth (1% yeast extract, 2% bacto-peptone, 2% glucose) for yeast species, and Potato Dextrose Broth (PDB) for A. niger .
구체적으로, 각 샘플당 세 번 중복되도록 멸균된 시험관을 이용하여 배양하였다. 혼합 용액은 각 시험관당 원하는 수의 균수를 접종한 후 24-48시간 동안 30°C에서 배양했다. ml 당 1.0 Х 105 cells의 효모 균체는 연속적으로 희석하여 0.1mL 씩 접종되었다. 한편, 본 발명의 실시예에 따른 화합물들을 1.0 Х 104 개/ml의 곰팡이포자를 연속 희석하여 0.1mL 씩 접종하였다. 이후, 본 발명의 화합물에 의한 최소 억제 농도를 평가하기 위하여 OD600에서 세포농도를 관찰하였다.Specifically, it was cultured using a sterilized test tube so as to overlap three times for each sample. The mixed solution was incubated at 30 °C for 24-48 hours after inoculating the desired number of bacteria per each test tube. The yeast cells of 1.0 Х 10 5 cells per ml were serially diluted and inoculated at 0.1 mL each. On the other hand, the compounds according to the embodiment of the present invention were serially diluted with 1.0 Х 10 4 pieces/ml mold spores and inoculated by 0.1 mL each. Then, the cell concentration was observed at OD 600 in order to evaluate the minimum inhibitory concentration by the compound of the present invention.
도 1은 효모 S. cerevisiae의 배양액에 실시예 1 내지 6에 따라 합성된 화합물 및 비교예 1 내지 2를 다양한 농도(0, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 mg/mL)로 추가하고, 48시간 동안 배양하면서 살균 효과를 관찰하기 위해 600 nm에서 흡광도를 관찰한 결과를 나타낸다.1 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 and 2 in various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 mg/mL) in a culture medium of yeast S. cerevisiae In addition, it shows the result of observing the absorbance at 600 nm to observe the bactericidal effect while culturing for 48 hours.
도 1을 보면, 비교예 1인 하이드로퀴논과 비교예 2인 1,2-헥산디올보다 본 발명의 화합물들의 살균력이 월등히 뛰어남을 확인할 수 있었다.Referring to FIG. 1, it was confirmed that the sterilizing power of the compounds of the present invention was significantly superior to that of the hydroquinone of Comparative Example 1 and the 1,2-hexanediol of Comparative Example 2.
도 2는 곰팡이 C. neoformans의 배양액에 실시예 1 내지 6에 따라 합성된 화합물 및 비교예 1 내지 2를 다양한 농도(0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL)로 추가하고, 48시간 동안 배양하면서 살균효과를 관찰하기 위해 600 nm에서 흡광도를 관찰한 결과를 나타낸다.Figure 2 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 and 2 at various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL in the culture medium of the fungus C. neoformans ) ), and shows the result of observing the absorbance at 600 nm to observe the sterilization effect while culturing for 48 hours.
도 2에 나타나듯이, 비교예 1인 하이드로퀴논과 비교예 2인 1,2-헥산디올보다 본 발명의 화합물들의 살균력이 다소 뛰어남을 확인할 수 있었다.As shown in FIG. 2, it was confirmed that the sterilizing power of the compounds of the present invention was somewhat superior to that of the hydroquinone of Comparative Example 1 and the 1,2-hexanediol of Comparative Example 2.
도 3은 효모 C. albicans의 배양액에 실시예 1 내지 6에 따라 합성된 화합물 및 비교예 1 내지 2를 다양한 농도(0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL)로 추가하고, 48시간 동안 배양하면서 살균효과를 관찰하기 위해 600 nm에서 흡광도를 관찰한 결과이다.3 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 to 2 in various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL in a culture medium of yeast C. albicans ) ), and the absorbance was observed at 600 nm to observe the sterilization effect while culturing for 48 hours.
도 3을 보면, 하이드로퀴논과 1,2-헥산디올보다 본 발명의 화합물들의 살균력이 월등히 뛰어남을 확인할 수 있었다.Referring to FIG. 3, it was confirmed that the sterilizing power of the compounds of the present invention was significantly superior to that of hydroquinone and 1,2-hexanediol.
도 4는 곰팡이 A. niger의 배양액에 실시예 1 내지 6에 따라 합성된 화합물 및 비교예 1 내지 2를 다양한 농도(0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL)로 추가하여 48시간 동안 배양하면서 살균효과를 관찰하기 위해 600 nm에서 흡광도를 관찰한 결과이며, 이를 통해 하이드로퀴논과 1,2-헥산디올보다 본 발명의 화합물들에 의한 살균력이 월등히 뛰어남을 확인할 수 있었다.Figure 4 shows the compounds synthesized according to Examples 1 to 6 and Comparative Examples 1 to 2 in various concentrations (0, 4, 2, 1, 0.5, 0.25, 0.25, 0.125, 0.0625 mg/mL in the culture medium of the fungus A. niger ) ) was added and the absorbance was observed at 600 nm to observe the sterilization effect while culturing for 48 hours. could
도 5는 4종의 균체에 대해 각 화합물의 농도별 살균효과를 비교한 그래프이다.5 is a graph comparing the sterilization effect by concentration of each compound for four types of cells.
도 5를 보면, 모든 효모균 및 곰팡이균에 대해 비교예 1 및 2에 비해, 본 발명의 실시예 1 내지 실시예 6의 살균력이 높은 결과를 확인할 수 있었다. 특히, 실시예 5(DS5105) 및 실시예 6(DS5148)은 저농도에서도 비교예 1 및 2에 비해 우수한 살균력을 나타냈으며, 이로부터 하이드로퀴논에 트라이플루오로기(-CF3)가 도입되는 경우 하이드로퀴논의 항균 효과를 현저히 증진시키는 효과가 있는 것을 확인할 수 있었다.Referring to FIG. 5 , it was confirmed that the sterilizing power of Examples 1 to 6 of the present invention was higher than those of Comparative Examples 1 and 2 for all yeast and mold bacteria. In particular, Example 5 (DS5105) and Example 6 (DS5148) exhibited superior sterilization power compared to Comparative Examples 1 and 2 even at low concentrations, from which a trifluoro group (-CF 3 ) is introduced into hydroquinone. It was confirmed that there was an effect of remarkably enhancing the antibacterial effect of quinone.
본 실험예에서는 효모균 2종(S. cerevisiae, C. albicans)과 곰팡이균 2종(C. neoformans, A. niger)에 대한 살균력을 살펴보았으나, 본 발명의 요지상 이외의 효모균 및 곰팡이균에 대해 사용하여도 동일한 결과를 얻을 수 있음은 이 분야에서 통상적인 지식을 가진 자에게 자명한 사항이다.In this experimental example, the sterilization power against two types of yeast bacteria ( S. cerevisiae , C. albicans ) and two types of fungi ( C. neoformans , A. niger ) was examined, but the It is obvious to a person having ordinary knowledge in this field that the same result can be obtained even if it is used for
상기에서는 본 발명의 바람직한 실시예를 참조하여 설명하였지만, 해당 기술 분야의 숙련된 당업자는 하기의 특허 청구 범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.Although the above has been described with reference to the preferred embodiment of the present invention, those skilled in the art can variously modify and change the present invention without departing from the spirit and scope of the present invention as set forth in the claims below. You will understand that you can.

Claims (7)

  1. 하기 화학식 1로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는, 항균제:An antibacterial agent comprising a trifluoromethylated hydroquinone derivative represented by the following formula (1):
    [화학식 1][Formula 1]
    Figure PCTKR2021010236-appb-img-000051
    Figure PCTKR2021010236-appb-img-000051
    상기 화학식 1에서,In Formula 1,
    R1, R2, R3, 및 R4 는 각각 독립적으로, 수소, 탄소수 1 내지 10의 알킬, 탄소수 1 내지 10의 알콕시, 할로겐, 및 -CF3 에서 선택되고, 단, R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이다.R 1 , R 2 , R 3 , and R 4 are each independently selected from hydrogen, alkyl having 1 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, halogen, and —CF 3 , with the proviso that R 1 , R 2 any one of , R 3 , and R 4 is —CF 3 .
  2. 제1항에 있어서,According to claim 1,
    상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알콕시인 것을 특징으로 하는 항균제.Any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 , and the remainder is hydrogen or a linear or branched alkoxy having 1 to 10 carbon atoms.
  3. 제1항에 있어서,According to claim 1,
    상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 할로겐인 것을 특징으로 하는 항균제.Any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 , and the remainder is hydrogen or halogen.
  4. 제1항에 있어서,According to claim 1,
    상기 R1, R2, R3, 및 R4 중 임의 하나는 -CF3 이고, 나머지는 수소 또는 탄소수 1 내지 10의 직쇄 또는 분지쇄 알킬인 것을 특징으로 하는 항균제.Any one of R 1 , R 2 , R 3 , and R 4 is —CF 3 , and the rest is hydrogen or a straight-chain or branched alkyl having 1 to 10 carbon atoms.
  5. 제1항에 있어서,According to claim 1,
    하기 화학식 1-1 내지 1-14 중 어느 하나에 의해 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 것을 특징으로 하는, 항균제:An antibacterial agent comprising a trifluoromethylated hydroquinone derivative represented by any one of the following formulas 1-1 to 1-14:
    [화학식 1-1][Formula 1-1]
    Figure PCTKR2021010236-appb-img-000052
    Figure PCTKR2021010236-appb-img-000052
    [화학식 1-2][Formula 1-2]
    Figure PCTKR2021010236-appb-img-000053
    Figure PCTKR2021010236-appb-img-000053
    [화학식 1-3][Formula 1-3]
    Figure PCTKR2021010236-appb-img-000054
    Figure PCTKR2021010236-appb-img-000054
    [화학식 1-4][Formula 1-4]
    Figure PCTKR2021010236-appb-img-000055
    Figure PCTKR2021010236-appb-img-000055
    [화학식 1-5][Formula 1-5]
    Figure PCTKR2021010236-appb-img-000056
    Figure PCTKR2021010236-appb-img-000056
    [화학식 1-6][Formula 1-6]
    Figure PCTKR2021010236-appb-img-000057
    Figure PCTKR2021010236-appb-img-000057
    [화학식 1-7][Formula 1-7]
    Figure PCTKR2021010236-appb-img-000058
    Figure PCTKR2021010236-appb-img-000058
    [화학식 1-8][Formula 1-8]
    Figure PCTKR2021010236-appb-img-000059
    Figure PCTKR2021010236-appb-img-000059
    [화학식 1-9][Formula 1-9]
    Figure PCTKR2021010236-appb-img-000060
    Figure PCTKR2021010236-appb-img-000060
    [화학식 1-10][Formula 1-10]
    Figure PCTKR2021010236-appb-img-000061
    Figure PCTKR2021010236-appb-img-000061
    [화학식 1-11][Formula 1-11]
    Figure PCTKR2021010236-appb-img-000062
    Figure PCTKR2021010236-appb-img-000062
    [화학식 1-12][Formula 1-12]
    Figure PCTKR2021010236-appb-img-000063
    Figure PCTKR2021010236-appb-img-000063
    [화학식 1-13][Formula 1-13]
    Figure PCTKR2021010236-appb-img-000064
    Figure PCTKR2021010236-appb-img-000064
    [화학식 1-14][Formula 1-14]
    Figure PCTKR2021010236-appb-img-000065
    Figure PCTKR2021010236-appb-img-000065
  6. 하기 화학식 2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는, 항균제:An antibacterial agent comprising a trifluoromethylated hydroquinone derivative represented by the following formula (2):
    [화학식 2][Formula 2]
    Figure PCTKR2021010236-appb-img-000066
    Figure PCTKR2021010236-appb-img-000066
    상기 화학식 2에서,In Formula 2,
    R11, R12, R13, 및 R14 는 각각 독립적으로, 수소 또는 할로겐에서 선택되고, 단, R11, R12, R13, 및 R14 중 적어도 하나 이상은 할로겐이다.R 11 , R 12 , R 13 , and R 14 are each independently selected from hydrogen or halogen, provided that at least one of R 11 , R 12 , R 13 , and R 14 is halogen.
  7. 제6항에 있어서, 하기 화학식 2-1 또는 2-2로 표시되는 트리플루오로메틸화된 하이드로퀴논 유도체를 포함하는 것을 특징으로 하는, 항균제:The antibacterial agent according to claim 6, characterized in that it comprises a trifluoromethylated hydroquinone derivative represented by the following formula 2-1 or 2-2:
    [화학식 2-1][Formula 2-1]
    Figure PCTKR2021010236-appb-img-000067
    Figure PCTKR2021010236-appb-img-000067
    [화학식 2-2][Formula 2-2]
    Figure PCTKR2021010236-appb-img-000068
    Figure PCTKR2021010236-appb-img-000068
PCT/KR2021/010236 2021-02-18 2021-08-04 Antibacterial agent comprising trifluoromethylated hydroquinone WO2022177078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210021513A KR102578908B1 (en) 2021-02-18 2021-02-18 Antifungal agents containing trifluoromethylated hydroquinone derivatives
KR10-2021-0021513 2021-02-18

Publications (1)

Publication Number Publication Date
WO2022177078A1 true WO2022177078A1 (en) 2022-08-25

Family

ID=82932033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/010236 WO2022177078A1 (en) 2021-02-18 2021-08-04 Antibacterial agent comprising trifluoromethylated hydroquinone

Country Status (2)

Country Link
KR (1) KR102578908B1 (en)
WO (1) WO2022177078A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240036878A (en) 2022-09-14 2024-03-21 영남대학교 산학협력단 Composition for inhibiting formation of Staphylococcus aureus biofilm comprising tetramethylbutylhydroquinone as an active ingredient

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368008A1 (en) * 1988-10-24 1990-05-16 Bayer Ag Fluorine-containing phenols
JPH03271244A (en) * 1990-03-19 1991-12-03 Central Glass Co Ltd Production of trifluoromethoxyphenol derivative
JP2005220039A (en) * 2004-02-03 2005-08-18 Ajinomoto Co Inc New antifungal agent fa200a
KR20070104545A (en) * 2005-01-05 2007-10-26 다우 글로벌 테크놀로지스 인크. Enhanced efficacy of fungicides in paper and paperboard
WO2011062259A1 (en) * 2009-11-20 2011-05-26 出光テクノファイン株式会社 Composition, antibacterial processing agent and antibacterial molded article
JP2019210250A (en) * 2018-06-05 2019-12-12 株式会社クラレ Preservative composition containing isopentyldiol

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368008A1 (en) * 1988-10-24 1990-05-16 Bayer Ag Fluorine-containing phenols
JPH03271244A (en) * 1990-03-19 1991-12-03 Central Glass Co Ltd Production of trifluoromethoxyphenol derivative
JP2005220039A (en) * 2004-02-03 2005-08-18 Ajinomoto Co Inc New antifungal agent fa200a
KR20070104545A (en) * 2005-01-05 2007-10-26 다우 글로벌 테크놀로지스 인크. Enhanced efficacy of fungicides in paper and paperboard
WO2011062259A1 (en) * 2009-11-20 2011-05-26 出光テクノファイン株式会社 Composition, antibacterial processing agent and antibacterial molded article
JP2019210250A (en) * 2018-06-05 2019-12-12 株式会社クラレ Preservative composition containing isopentyldiol

Also Published As

Publication number Publication date
KR102578908B1 (en) 2023-09-13
KR20220117977A (en) 2022-08-25

Similar Documents

Publication Publication Date Title
WO2022177078A1 (en) Antibacterial agent comprising trifluoromethylated hydroquinone
Kobayashi et al. Pironetin, a novel plant growth regulator produced by Streptomyces sp. NK10958 I. Taxonomy, production, isolation and preliminary characterization
WO2021071029A1 (en) Bacillus velezensis ce 100 strain and composition for controlling plant-pathogenic fungi using same
WO2011081398A2 (en) Surface treatment method for a substrate using denatured urushiol derived from toxicodendron vernicifluum
WO2013042900A2 (en) Novel strain bacillus vallismortis bso7m capable of promoting growth of plant and confering cold resistance on plant and microbial formulation comprising the same
WO2010035947A2 (en) Method for preparing 1-methyl cyclopropene and adding same to plants
WO2019074322A1 (en) Organic compound and organic electroluminescent device comprising same
WO2010090458A2 (en) Composition for controlling harmful algae
WO2022114417A1 (en) Penicillium paxilli strain having effect of preventing damage to plants caused by disease and harmful insects, and use thereof
WO2018008920A1 (en) Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
WO2016163741A1 (en) Polymer containing aziridine and method for producing same
WO2021162226A1 (en) Bacillus subtilis jck-1398 strain inducing resistance in various plants, and composition and method for controlling pine wilt disease by using same
ES2166269A1 (en) Process for the production of 2-(2-pyridinylmethylsulphinyl)-1h-benzimidazoles
WO2015163682A1 (en) Recombinant microorganism having enhanced ability to produce 2,3-butanediol, and method for producing 2,3-butanediol using same
WO2018093199A2 (en) Novel microorganism bacillus oryzicola yc7011 producing bacillopeptin-series cyclic lipopeptide, and microbial formulation including same
WO2017195961A1 (en) Preservative for externally-applied dermal preparation, and cosmetic composition and pharmaceutical composition each containing same
EP2247644A2 (en) Ph-sensitive polyethylene oxide co-polymer and synthetic method thereof
WO2012134188A2 (en) Novel oxazolidinone derivative and medical composition containing same
WO2014010990A1 (en) Novel pyridine derivatives and method for preparation of intermediate compound for producing sulfonylurea herbicides using the same
WO2023055109A1 (en) Method for producing polyhydroxyalkanoate, polyhydroxyalkanoate produced using same, and dry fermenter for producing polyhydroxy alkanoate
WO2022050774A1 (en) Novel imidazole derivative salt having antifungal activity, and use thereof
WO2019132600A9 (en) Feed composition containing bacilius subtilus strain, bacilius pumilus strain, and bacilius lichenformis strain as active ingredients for preventing or treating acute hepatopancreatic necrosis disease or white spot syndrome
WO2020027620A1 (en) Composition and method for preparation of dihydroxy fatty acid or lipid mediator by using combined lipoxygenase reactions
WO2022010170A1 (en) Novel esterase, polynucleotide encoding same, and microoganism including same
WO2023277590A1 (en) Method for preparing alkyl-d-alaninate, alkyl-d-alaninate, alkyl-d-alaninate derivative, and pharmaceutical or agricultural product including same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21926877

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21926877

Country of ref document: EP

Kind code of ref document: A1